mRNA and LNPs: Molecules, Delivery, Manufacturing, and Analytics
mRNA / LNP
This guide separates RNA products, LNP delivery platforms, and development and manufacturing services. Compare the RNA type, target tissue, study stage, and process and analytical capabilities rather than treating a platform label as evidence of performance.
Questions to ask first
- Does the program use linear mRNA, saRNA, or an adjacent RNA approach, and what tissue and route of administration does it target?
- Which model supports the delivery findings, and is expression and tolerability evidence relevant to the intended tissue disclosed?
- Do the services cover the required RNA production, LNP formulation, characterization, and quality expectations for the intended development stage?
Key terms
- mRNA and saRNA
- Linear mRNA and self-amplifying RNA categories are tracked separately in this map rather than combining their programs and results.
- LNP
- The lipid nanoparticle delivery category; a platform name alone does not establish its tissue suitability, administration route, or development stage.
- Analytics and characterization
- Work used to understand RNA and delivery-system quality and attributes, assessed separately from evidence of therapeutic efficacy.
Evidence and scope
The topic also identifies adjacent approaches, including circular RNA and nonlipid delivery. Preclinical expression or delivery findings do not establish efficacy in humans. Results from different RNA constructs, lipid compositions, doses, and models should not be directly ranked, and GMP capabilities require verification for the specific service and development stage.
Technology snapshot: 2026-11-01 · Research methods
